Study Summary
This trial tests the safety, side effects, and how the body handles a drug given by injection to people with moderate to severe Alzheimer's.
- Atopic Dermatitis
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 28 Secondary · Reporting Duration: Pre-dose on Day 1 through Day 85
Trial Safety
Phase-Based Safety
Trial Design
8 Treatment Groups
NM26-2198 50 mg
1 of 8
NM26-2198 600 mg
1 of 8
NM26-2198 10 mg
1 of 8
NM26-2198 150 mg
1 of 8
NM26-2198
1 of 8
NM26-2198 300 mg
1 of 8
NM26-2198 400 mg
1 of 8
Placebo
1 of 8
Experimental Treatment
Non-Treatment Group
102 Total Participants · 8 Treatment Groups
Primary Treatment: NM26-2198 50 mg · Has Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What implications does the use of NM26-2198 10 mg have for human health?
"Unsurprisingly, NM26-2198 10 mg earned a score of 1 due to its lack of safety and efficacy data associated with Phase 1 trials." - Anonymous Online Contributor
What is the size of the cohort receiving this clinical trial treatment?
"Right. Clinicaltrials.gov offers evidence that this medical trial, which was first announced on May 10th 2023, is actively enrolling participants. This trial seeks to enrol 102 patients from one clinical centre." - Anonymous Online Contributor
Are there any remaining vacancies to be filled for this research effort?
"Yes, the clinical trial is currently accepting participants. Initially posted in May 10th 2023 and recently edited on May 5th 2023 , this study needs 102 volunteers to be recruited from one medical site." - Anonymous Online Contributor